Amgen’s Brief in Opposition to Sandoz’s Petition for Supreme Court Review, and Amicus Brief by The Biosimilars Council in Support of Sandoz

Amgen v. Sandoz (filgrastim)  •  BPCIA and Related U.S. Statutes  •  U.S. Biosimilar Litigation News

As we posted yesterday, Amgen has filed a brief in opposition to Sandoz’s petition to the Supreme Court for review of the Federal Circuit’s decision in Amgen v. Sandoz.  Amgen’s brief is now available here.

The Biosimilars Council also filed a brief, as amicus curiae in support of Sandoz’s petition.  Their amicus brief is available here.

Stay tuned for further updates and analysis from the Big Molecule Watch.

Download PDF

Comments are closed.